Polymyalgia rheumatica

Czech version

Authors: Petr Němec ¹; Andrea Šprláková-Puková ²; Zdeněk Řehák ³
Authors‘ workplace: Revmatologická ambulance II. interní kliniky LF MU a FN u sv. Anny Brno ¹; Klinika radiologie a nukleární medicíny LF MU a FN Brno, pracoviště Bohunice ²; Oddělení nukleární medicíny Masarykova onkologického ústavu, Brno ³
Published in: Vnitř Lék 2018; 64(2): 173-183
Category: Reviews

Overview

Polymyalgia rheumatica is the most frequent inflammatory disease of people over 50 years of age. It mainly affects the Caucasian race and roughly 2–3 times as many women. From the viewpoint of etiology, polymyalgia rheumatica is a complex disease. Involved in its origin is genetic predisposition, factors of age and outer environment. 16–21 % of patients with polymyalgia rheumatica may at the same time have symptoms of giant cell arteritis. Diagnosis is made primarily on the basis of clinical symptoms and it is supported by the presence of laboratory signs of inflammation. There is no specific diagnostic test available for diagnosing polymyalgia rheumatica. In recent time modern imaging devices, e.g. ultrasonography or positron emission tomography, can be used in diagnosing the disease. In the past a number of diagnostic and classification criteria were established which may be used in diagnosing of polymyalgia rheumatica in general practice. The differential diagnostics of the disease is extensive. Before the treatment commencement it is necessary to rule out the presence of another disease with manifestations simulating polymyalgia rheumatica. The treatment strategy should draw on the current EULAR/ACR Recommendations for the treatment of polymyalgia rheumatica issued in 2015.

Key words:
polymyalgia rheumatica – positron emission tomography – prognosis – treatment – ultrasonography

Sources

1. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis 2006; 65(8): 1093–1098. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2005.046912>.

2. Rooney PJ, Rooney J, Balint G et al. Polymyalgia rheumatica: 125 years of epidemiological progress? Scott Med J 2015; 60(1): 50–57. Dostupné z DOI: <http://dx.doi.org/10.1177/0036933014551115>.

3. Sonnenblick M, Nesher G, Friedlander Y et al. Giant cell arteritis in Jerusalem: a 12 year epidemiological study. Br J Rheumatol 1994; 33(10): 938–941.

4. Salvarani C, Gabriel SE, O‘Fallon WM et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum 1995; 38(3): 369–373.

5. Gonzalez-Gay MA. Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. Arthritis Res 2001; 3(3): 154–157. Dostupné z DOI: <http://dx.doi.org/10.1186/ar293>.

6. Boiardi L, Salvarani C, Timms JM et al. Interleukin-1 cluster and tumor necrosis factor-alpha gene polymorphisms in polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18(6): 675–681.

7. Tarlow JK, Blakemore AI, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91(4): 403–404.

8. Coll-Vinent B, Vilardell C, Font C et al. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis 1999; 58(3): 189–192.

9. Pulsatelli L, Meliconi R, Boiardi L et al. Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. Clin Exp Rheumatol 1998; 16(3): 263–268.

10. Ceribelli A, Yao B, Dominguez-Gutierrez PR et al. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 2011; 13(4): 229. Dostupné z DOI: <http://dx.doi.org/10.1186/ar3377>.

11. Furer V, Greenberg JD, Attur M et al. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clinical Immunology 2010; 136(1): 1–15. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clim.2010.02.005>.

12. Hunter RG, McEwen BS. Stress and anxiety across the lifespan: structural plasticity and epigenetic regulation. Epigenomics 2013; 5(2): 177–194. Dostupné z DOI: <http://dx.doi.org/10.2217/epi.13.8>.

13. Razin A, Cedar H. DNA methylation and gene expression. Microbiol Rev 1991; 55(3): 451–458.

14. Bird HA, Esselinkx W, Dixon AS et al. An evaluation of criteria for Polymyalgia Rheumatica. Ann Rheum Dis 1979; 38(5): 434–439.

15. Mowat AG, Hazleman BL Polymyalgia rheumatica – a clinical study with particular reference to arterial disease. J Rheumatol 1984; 11(5): 580–581.

16. Cimmino MA, Caporali R, Montecucco CM et al. A seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 1990; 49(7): 521–523.

17. Kinmont PDC, McCollum DI. The aetiology, pathology and course of giant cell arteritis. The possible role of light sensitivity. Brit J Dermatol 1965; 77: 193–202.

18. Chuang TY, Hunder GG, Ilstrup DM et al. Polymyalgia rheumatica: a 10 year epidemiologic and clinical study. Ann Intern Med 1982; 97(5): 672–680.

19. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis 2006; 65(8): 1093–1098. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2005.046912>.

20. Coomes EN, Ellis RM, Kay AG. A prospective study of 102 patients with the polymyalgia rheumatica syndrome. Rheumatology 1976; 15(4): 270–276.

21. Perfetto F, Moggi-Pignone A, Becucci A et al. Seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 2005; 64(11): 1662–1663. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2005.038901>.

22. Narvaez J, Clavaguera MT, Nolla-Sole JM et al. Lack of association between infection and onset of polymyalgia rheumatica. J Rheumatol 2000; 27(4): 953–957.

23. Bacon PA, Doherty SM, Zuckerman AJ. Hepatitis-B antibody in polymyalgia rheumatica. Lancet 1975; 2(7933): 476–478.

24. Bridgeford PH, Lowenstein M, Bocanegra TS et al. Polymyalgia rheumatica and giant cell arteritis: histocompatibility typing and hepatitis-B infection studies. Arthritis Rheum 1980; 23(4): 516–518.

25. Buchwald D, Sullivan JL, Leddy S et al. Chronic Ebstein-Barr virus infection’ syndrome and polymyalgia rheumatica. J Rheumatol 1988; 15(3): 479–482.

26. Gonzalez-Gay MA, Vasquez-Rodriguez TR, Lopez-Diaz MJ et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61(10): 1454–1461. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24459>.

27. Salvarani C, Cantini F, Boiardi L et al. Polymyalgia rheumatica and giant cell arteritis. N Eng J Med 2002; 347(4): 261–267. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra011913>.

28. Ross RT. From the Tadhkirat of Ali Ibn Isa of Baghdad (c 940–1010 AD) – an ancient description of what may be temporal arteritis. J Neurol Neurosurg Psychiatry 1988; 51(4): 528.

29. Calvo-Romero JM. Giant cell arteritis. Postgrad Med J 2003; 79(935): 511–515.

30. Mackie SL, Pease CT. Diagnosis and management of giant cell arteritis and polymyalgia rheumatica: challenges, controversies and practical tips. Postgrad Med J 2013; 89(1051): 284–292. Dostupné z DOI: <http://dx.doi.org/10.1136/postgradmedj-2012–131400>.

31. Salvarani C, Cantini F, Olivieri I et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997; 127(1): 27–31.

32. Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010; 49(1): 186–190. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kep303a>.

33. Dasgupta B, Salvarani C, Schirmer M et al. Members of the American College of Rheumatology Work Group for Development of Classification Criteria for PMR Development of classification criteria for polymyalgia rheumatica (PMR): results from an expert work group meeting and a wider survey. J Rheumatol 2008; 35(2): 270–277.

34. Hutchings A, Hollywood J, Lamping D et al. Clinical outcomes, quality of life and diagnostic uncertainty in the first year in polymyalgia rheumatica. Arthritis Rheum 2007; 57(5): 803–809. Dostupné z DOI: <http://dx.doi.org/10.1002/art.22777>.

35. Leeb BF, Bird HA, Nesher G et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis 2003; 62(12): 1189–1194.

36. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004; 63(10): 1279–1283. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2003.011379>.

37. Leeb BF, Rintelen B, Sautner J et al. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 2007; 57(5): 810–815. Dostupné z DOI: <http://dx.doi.org/10.1002/art.22771>.

38. Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71(4): 484–492. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2011–200329>.

39. Ortiz Z, Tugwell P. Raised ESR in polymyalgia rheumatica no longer a sine qua non. Lancet 1996; 348(9019): 4–5.

40. Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate: a more benign syndrome. Arch Int Med 1997; 157(3): 317–320.

41. Codreanu C, Enache L. Is ultrasound changing the way we understand rheumatology? Including ultrasound examination in the classification criteria of polymyalgia rheumatica and gout. Med Ultrason 2015; 17(1): 97–103. Dostupné z DOI: <http://dx.doi.org/10.11152/mu.2013.2066.171.ccle>.

42. Sakellariou G, Iagnocco A, Riente L et al. Ultrasound imaging for the rheumatologist. XLIII. Ultrasonographic evaluation of shoulders and hips in patients with polymyalgia rheumatica: a systematic literature review. Clin Exp Rheumatol 2013; 31(1): 1–7.

43. Klauser A, Demharter J, De Marchi A et al. Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: results from the IACUS study group. Eur Radiol 2005; 15(12): 2404–2410. Dostupné z DOI: <http://dx.doi.org/10.1007/s00330–005–2884–9>.

44. Klauser AS, De Zordo T, Bellmann-Weiler R et al. Feasibility of second-generation ultrasound contrast media in the detection of active sacroiliitis. Arthritis Rheum 2009; 61(7): 909–916. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24648>.

45. Blockmans D, De Ceuninck L, Vanderscheueren S et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology 2007; 46(4): 672–677. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kel376>.

46. Salvarani C, Pipitone N, Versari A et al. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012; 8(9): 509–521. Dostupné z DOI: <http://dx.doi.org/10.1038/nrrheum.2012.97>.

47. Yamashita H, Kubota K, Takahashi Y et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large vessel vasculitis. Mod Rheumatol 2012; 22(5): 705–711. Dostupné z DOI: <http://dx.doi.org/10.1007/s10165–011–0581-x>.

48. Rehak Z, Vasina J, Nemec P et al. Various forms of 18F-FDG PET and PET/CT findings in patients with polymyalgia rheumatica. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159(4): 629–636. Dostupné z DOI: <http://dx.doi.org/10.5507/bp.2015.026>.

49. Lopez-Hoyos M, Ruiz de Alegria C, Blanco R et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 2004; 43(5): 655–657. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/keh143>.

50. Muller S, Hider SL, Belcher J et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis 2014; 73(10): 1769–1773. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013–203465>.

51. Ji J, Liu X, Sundquist K et al. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology (Oxford) 2010; 49(6): 1158–1163. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/keq040>.

52. Dejaco C, Singh YP, Perel P et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015; 74(10): 1799–1807. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2015–207492>.

53. Duru N, van der Goes MC, Jacobs JWG et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72(12): 1905–1913. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2013–203249>.

54. Grossman JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62(11): 1515–1526. Dostupné z DOI: <http://dx.doi.org/10.1002/acr.20295>. Erratum inArthritis Care Res (Hoboken) 2012; 64(3): 464.

55. Van der Goes MC, Jacobs JWG, Boers M et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69(11): 1913–1919. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2009.124958>.

56. Hoes JN, Jacobs JWG, Boers M et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66(12): 1560–1567. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2007.072157>.

57. Dasgupta B, Dolan AL, Panayi GS et al. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998; 37(2): 189–195.

58. Caporali R, Cimmino MA, Ferraccioli G et. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141(7): 493–500.

59. Van der Veen MJ, Dinant HJ, van Booma-Frankfort C et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55(4): 218–223. Erratum in Ann Rheum Dis 1996; 55(8): 563.

60. Ferraccioli G, Salaffi F, De Vita S et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23(4): 624–628.

61. Nazarinia AM, Moghimi J, Toussi J. Efficacy of methotrexate in patients with polymyalgia rheumatica. Koomesh 2013; 14(3): 265–270.

62. Devauchelle V, Berthelot JM, Cornec D et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis 2016; 75(8):1506–1510. Dostupné z DOI: <http://doi: 10.1136/annrheumdis-2015–208742>.

63. Lally L, Forbess L, Hatzis C et al. Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica. Arthritis Rheumatol 2016; 68(10): 2550–2554. Dostupné z DOI: <http://dx.doi.org/10.1002/art.39740>.

64. Hancock AT, Mallen CD, Muller S et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ 2014; 186(13): E495-E501. Dostupné z DOI: <http://dx.doi.org/10.1503/cmaj.140266>.

65. Kremers HM, Reinalda MS, Crowson CS et al. Direct medical costs of polymyalgia rheumatica. Arthritis Rheum 2005; 53(4): 578–584. Dostupné z DOI: <http://dx.doi.org/10.1002/art.21311>.

66. Warrington KJ, Jarpa EP, Crowson CS et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Res Ther 2009; 11(2): R50. Dostupné z DOI: <http://dx.doi.org/10.1186/ar2664>.

67. González-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26(6): 1326–1332.

68. Narváez J, Nolla-Sole JM, Clavaguera MT et al. Long-term therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 1999; 26(9): 1945–1952.

69. Hutchings A, Hollywood J, Lamping DL et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007; 57(5): 803- 809. Dostupné z DOI: <http://dx.doi.org/10.1002/art.22777>.

70. Kremers HM, Reinalda MS, Crowson CS et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005; 32(1): 65–73.

71. Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis: a prospective two-year study in 273 patients. Scand J Rheumatol 2001; 30(5): 260–267.

72. Salvarani C, Cantini F, Niccoli L et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective follow-up study. Arthritis Rheum 2005; 53(1): 33–38. Dostupné z DOI: <http://dx.doi.org/10.1002/art.20901>.

73. Cimmino MA, Parodi M, Caporali R et al. Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann NY Acad Sci 2006; 1069: 315–321. Dostupné z DOI: <http://dx.doi.org/10.1196/annals.1351.030>.

74. Dasgupta B, Dolan AL, Panayi GS et al. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998; 37(2): 189–195.

75. Gabriel SE, Sunku J, Salvarani C et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40(10): 1873–1878. Dostupné z DOI: <http://dx.doi.org/10.1002/1529–0131(199710)40:10<1873::AID-ART22>3.0.CO;2-V>.